NASDAQ$OSUR

OraSure Technologies Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Reported record revenue and announced new collaborations, focusing on core growth.

OraSure Technologies reported a record revenue of $155.0 million in Q1 2023, a 129% increase from Q1 2022. The company saw growth in InteliSwab® test revenue and signed three new molecular partnerships. They also reduced their non-production workforce by 11% and improved their cash position to $112.4 million.

  • Net revenues increased by 129% to $155.0 million, a new record for the Company.
  • InteliSwab® test revenue increased 33% sequentially to $118.3 million due to record test volume.
  • GAAP gross margin increased to 42.5% compared to 35.9% in the first quarter of 2022.
  • Cash and short-term investments increased to $112.4 million as of March 31, 2023.

Headline financials

Total Revenue

$155M

Previous: $67.7M+128.9%
EPS (adj)

$0.47

Previous: -$0.28+267.9%
Capital Expenditures

-$1.19M

Previous: -$20.2M+94.1%
Free Cash Flow

$26M

Previous: -$40.2M+164.8%
Net Income

$27.2M

Previous: -$20M+236.3%
Operating Income

$24.3M

Previous: -$16M+252.2%
Gross Profit

$65.8M

Previous: $24.3M+171.2%
Cash & Equivalents

$90.2M

Previous: $70.7M+27.5%
Total Assets

$459M

Previous: $436M+5.5%
Stock-Based Comp

$2.66M

Previous: $3.52M-24.7%

Revenue & EPS history

OraSure · Revenue · Quarterly

$155M

Q1 2023+128.9%vs Q1 2022
Beat estimate in 13 of 14 quarters(93%)
ActualEstimate

Forward guidance

The Company is guiding toward 2Q23 revenue of $62 to $67 million. The Company anticipates experiencing some temporary margin headwinds in Q2 2023 predominantly due to InteliSwab® pricing mix.

Tailwinds

  • Actively working with public health partners
  • Ensuring warm-base manufacturing
  • Infectious disease outbreak readiness
  • Utilizing existing funds appropriated under InteliSwab® contracts
  • Plans to deliver additional cost savings beyond the $15 million announced in Q1 2023.

Headwinds

  • Lower April ordering activity from the U.S. government
  • Guiding to InteliSwab® revenue of $25 to $30 million in the second quarter representing current government program orders.
  • Experiencing some temporary margin headwinds in Q2 2023
  • Headwinds due to InteliSwab® pricing mix.
  • Given lower April ordering activity from the U.S. government in respect to the school testing program

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-2.1%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-2.4%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+31.7%

Q2 2023

Best reaction

-32.1%

Q2 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.2%-2.9%
Q4 2025+10.0%+6.4%+7.1%
Q3 2025-6.6%-4.3%-3.1%
Q1 2025-6.8%-5.0%+3.6%
Q4 2024-23.5%-10.8%-14.2%
Q3 2024-1.2%-1.2%-8.9%
Q2 2024+2.6%-0.2%+5.7%
Q1 2024-8.8%-6.9%-15.3%
Q4 2023+10.3%+3.7%-12.3%
Q3 2023+4.9%+14.5%+22.2%
Q2 2023+31.7%+43.9%+42.8%
Q1 2023+9.2%-20.8%-22.3%
Q4 2022+10.4%+18.8%+30.1%
Q3 2022+0.7%+20.8%+18.5%
Q2 2022+28.3%+38.6%+18.8%
Q1 2022-8.9%-3.9%-48.8%
Q4 2021-1.3%-0.8%-13.0%
Q3 2021-4.9%-7.7%-19.8%
Q2 2021+1.2%-0.7%-4.1%
Q1 2021+5.0%+5.1%+0.2%
Q4 2020-2.3%+2.1%+1.5%
Q3 2020-15.6%-15.4%-20.6%
Q2 2020-32.1%-24.6%-46.9%
Q1 2020+6.1%+15.6%-33.1%
Q4 2019-6.7%-6.1%+8.5%
Q3 2019-3.1%-6.9%-10.3%
Q2 2019-3.3%-5.2%-14.4%
Q1 2019-8.0%-12.6%-12.7%
Q4 2018-25.5%-18.3%-14.8%
Q3 2018-8.7%-6.6%-15.0%
Q2 2018-0.6%-1.0%-5.8%
Q1 2018-15.4%-11.0%-2.4%
Q4 2017-12.8%-13.4%-9.5%
Q3 2017-30.3%-26.6%-13.8%
Q2 2017+13.5%+19.4%+17.4%
Q1 2017+16.9%+10.9%+17.6%
Q4 2016+18.9%+18.9%+29.9%
Q3 2016-0.1%+1.4%+14.3%
Q2 2016+4.6%+8.5%+30.7%
Q1 2016-6.6%
Q4 2015+14.7%
Q3 2015+0.4%
Q2 2015+7.0%
Q1 2015-12.3%
Q4 2014-11.9%
Q3 2014+2.9%
Q2 2014-7.7%
Q1 2014-9.2%
Q4 2013+9.5%
Q3 2013-0.3%
Q2 2013+10.2%
Q1 2013-0.4%
Q4 2012-12.4%
Q3 2012-16.4%
Q2 2012-7.1%
Q1 2011+5.0%
Q1 2012-5.9%
Q4 2011+4.6%
Q3 2011-5.6%
Q4 2010-12.5%
Q2 2011-12.5%
Q3 2010+6.6%
Q2 2010-7.0%
Q1 2010-15.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro